Amber Therapeutics Funding: $100M Raised, Series A (2024)
Amber Therapeutics is a Biotech company based in London, United Kingdom. It has raised $100M in total funding. Latest round: Series A.
Amber Therapeutics funding overview
Amber Therapeutics is a Biotech company based in London, United Kingdom. Amber Therapeutics has raised $100M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series A announced in January 2024. The round record for Amber Therapeutics runs through 2024; nothing later has been disclosed. Investors on record include New Enterprise Associates (NEA), Oxford Science Enterprises, 8VC, F-Prime Capital, Lightstone Ventures, Intuitive Ventures. 6 distinct backers are named across the disclosed rounds.
Amber Therapeutics has raised $100M in total disclosed funding across the rounds on record.
Who has invested in Amber Therapeutics?
New Enterprise Associates (NEA), Oxford Science Enterprises, 8VC, F-Prime Capital, Lightstone Ventures, Intuitive Ventures are named among the investors backing Amber Therapeutics.
What was the latest Amber Therapeutics funding round?
The most recent disclosed round is a Series A, announced in January 2024.
Where is Amber Therapeutics based?
Amber Therapeutics is based in London, United Kingdom.
What sector does Amber Therapeutics operate in?
Amber Therapeutics is tracked under Biotech from London, United Kingdom, with $100M in disclosed funding.
When did Amber Therapeutics last raise?
The last disclosed Amber Therapeutics round closed in January 2024 at Series A.
Amber Therapeutics totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related Biotech companies in London below to benchmark round size and investor mix.
